← Leaderboards
James W Janetka
Washington University
$9,104,937
Attributed
$16,807,532
Total exposure
9
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,807,532 · 9
By mechanism
R01$13,176,258 · 5
U19$3,031,322 · 2
R43$599,952 · 2
Top collaborators
- Makedonka Mitreva12 shared
- Sara Lustigman7 shared
- Scott J Hultgren4 shared
- Judy Sakanari4 shared
- L David Sibley4 shared
- Lidija Klampfer2 shared
Most similar at Washington University
Same institution · by research overlap
- Scott J Hultgren$48,876,558
- Makedonka Mitreva$12,990,587
- Warwick Grant$1,648,996
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsPropertyIn VitroDesignIn VivoDrug KineticsInfectionAnimal ModelInnovationStructureNovel TherapeuticsEvaluationIn Vivo EvaluationLeadSmall MoleculeInhibitorPre-ClinicalAnalogDockingAreaPharmaceutical ChemistryToxic EffectProteinsDrug Discovery
Grant awards (27)
Innovative therapeutic strategies to support elimination of river blindness$805,959
R01 · FY2025 · AI
Optimizing CDPK1 inhibitors for chronic toxoplasmosis$777,256
R01 · FY2025 · AI
Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs$721,872
R01 · FY2025 · AI
Rational design and synthesis of small molecule inhibitors targeting unique pathogenic mechanisms in Gram- and Gram+ bacteria important in UTI$697,215
U19 · FY2025 · AI · contact PI
Innovative therapeutic strategies to support elimination of river blindness$805,271
R01 · FY2024 · AI
Optimizing CDPK1 inhibitors for chronic toxoplasmosis$777,256
R01 · FY2024 · AI
Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs$759,307
R01 · FY2024 · AI
Rational design and synthesis of small molecule inhibitors targeting unique pathogenic mechanisms in Gram- and Gram+ bacteria important in UTI$654,484
U19 · FY2024 · AI · contact PI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$410,000
R01 · FY2024 · EY
Innovative therapeutic strategies to support elimination of river blindness$834,159
R01 · FY2023 · AI
Optimizing CDPK1 inhibitors for chronic toxoplasmosis$780,588
R01 · FY2023 · AI
Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs$773,850
R01 · FY2023 · AI
Rational design and synthesis of small molecule inhibitors targeting unique pathogenic mechanisms in Gram- and Gram+ bacteria important in UTI$680,528
U19 · FY2023 · AI · contact PI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$410,000
R01 · FY2023 · EY
Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs$788,290
R01 · FY2022 · AI
Optimizing CDPK1 inhibitors for chronic toxoplasmosis$787,253
R01 · FY2022 · AI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$397,700
R01 · FY2022 · EY
Rational design and synthesis of small molecule inhibitors targeting unique pathogenic mechanisms in Gram- and Gram+ bacteria important in UTI$360,857
U19 · FY2022 · AI · contact PI
Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs$817,605
R01 · FY2021 · AI
Rational design and synthesis of small molecule inhibitors targeting unique pathogenic mechanisms in Gram- and Gram+ bacteria important in UTI$638,238
U19 · FY2021 · AI · contact PI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$409,999
R01 · FY2021 · EY
SMALL MOLECULE BACTERIAL LECTIN ANTAGONISTS FOR UTI TREATMENT AND PREVENTION$549,282
R01 · FY2020 · DK · contact PI
SMALL MOLECULE BACTERIAL LECTIN ANTAGONISTS FOR UTI TREATMENT AND PREVENTION$544,748
R01 · FY2019 · DK · contact PI
Inhibitors of proâHGF activation overcome resistance to antiâEGFR therapy$299,972
R43 · FY2019 · CA
SMALL MOLECULE BACTERIAL LECTIN ANTAGONISTS FOR UTI TREATMENT AND PREVENTION$540,213
R01 · FY2018 · DK · contact PI
Targeting Hepatocyte Growth Factor Processing and Activation in Lung Cancer$299,980
R43 · FY2018 · CA
SMALL MOLECULE BACTERIAL LECTIN ANTAGONISTS FOR UTI TREATMENT AND PREVENTION$485,650
R01 · FY2017 · DK · contact PI